NDA 020555 · Haleon US Holdings
Axid Ar
Nizatidine · Oral
Last checked: Nov 20, 2026Latest source record: Apr 9, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
May 9, 1996
Approved uses
3
Original approval plus efficacy supplements
Registered trials
10
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 1, 1998 Supplement 4 · Efficacy ReviewLabelLetter
- Apr 1, 1998 Supplement 3 · Efficacy LabelReviewLetter
- May 9, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
- AXID AR · NIZATIDINE 75MG · TABLET, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Nizatidine" as an intervention, any sponsor and status, largest first.
- Prophylaxis for Aspiration of Gastric Contents.Pivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT02703896 · 1,920 participants · Start Jan 2012 · Primary completion Jan 2012
Drug: Drug either PPIS or H2RA and prokinetics · For: Pulmonary Aspiration of Gastric Contents
- Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With GastritisPivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT05072938 · 260 participants · Start Sep 30, 2021 · Primary completion Dec 15, 2022
Drug: Mucotra SR Tablet 150mg; Axid Capsule 150mg · For: Gastritis
Sites: Seoul, South Korea
- Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)Pivotal-lookingCompleted
Braintree LaboratoriesIndustry
NCT00373334 · 138 participants · Start Aug 2006 · Primary completion Feb 2008
Drug: nizatidine (axid); nizatidine (axid) and 1 more · For: Gastroesophageal Reflux Disease; GERD; Heartburn
Sites: Hot Springs, Arkansas; Jonesboro, Arkansas; Little Rock, Arkansas · 26 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT00486005 · 74 participants · Start Feb 2003
Drug: Olanzapine Hydrochloride; Nizatidine and 1 more · For: Schizophrenia
Sites: Rio de Janeiro, Brazil
- [KJ-INT-002] BE StudyStatus unknown
Kukje PharmaAcademic, hospital or other
NCT03509831 · 37 participants · Start Nov 2, 2017 · Primary completion Jan 24, 2018
Drug: INT-2150; Irsogladine maleate 2 mg+Nizatidine 150 mg · For: Gastritis
Sites: Seongnam-si, South Korea
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01161927 · 26 participants · Start Jul 2004 · Primary completion Sep 2004
Drug: Nizatidine; Axid · For: Healthy
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01161940 · 26 participants · Start Jul 2004 · Primary completion Sep 2004
Drug: Nizatidine; Axid · For: Healthy
Adil BharuchaAcademic, hospital or other
NCT02232308 · 24 participants · Start Jul 2014 · Primary completion Sep 2014
Drug: Nizatidine; Lisinopril and 1 more · For: Gastroparesis
Sites: Rochester, Minnesota · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ranitidine Use and Incident Cancer in a Multinational Cohort.
You SC, Seo SI, Falconer T, et al. · JAMA Netw Open 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Agarwal SM, Stogios N, Ahsan ZA, et al. · Cochrane Database Syst Rev 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis.
Hegde NC, Mishra A, Maiti R, et al. · Gen Hosp Psychiatry 2024 · Network Meta-Analysis
- Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study.
Kang D, Choi MG, Shim KN, et al. · World J Gastroenterol 2024 · Clinical Trial, Phase IV, Comparative Study
- Nizatidine (AXID).
· Med Lett Drugs Ther 1988 · Clinical Trial
- Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.
Stogios N, Agarwal SM, Maksyutynska K, et al. · JAMA Psychiatry 2026 · Systematic Review, Network Meta-Analysis
Sponsor: Haleon US Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.